期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 47, 期 10, 页码 3123-3129出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.47.10.3123-3129.2003
关键词
-
资金
- NIGMS NIH HHS [R01 GM062920, U01 GM062920, GM 62920, R37 GM053386, GM 53386, R01 GM062920-05, R01 GM053386] Funding Source: Medline
We designed, synthesized, and identified UIC-94017 (TMC114), a novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) containing a 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF) and a sulfonamide isostere which is extremely potent against laboratory HIV-1 strains and primary clinical isolates (50% inhibitory concentration [IC50], similar to0.003 muM; IC90, similar to0.009 muM) with minimal cytotoxicity (50% cytotoxic concentration for CD4(+) MT-2 cells, 74 muM). UIC-94017 blocked the infectivity and replication of each of HIV-1(NL4-3) variants exposed to and selected for resistance to saquinavir, indinavir, nelfinavir, or ritonavir at concentrations up to 5 muM (IC(50)s, 0.003 to 0.029 muM), although it was less active against HIV-1(NL4-3) variants selected for resistance to amprenavir (IC(50)s, 0.22 muM). UIC-94017 was also potent against multi-PI-resistant clinical HIV-1 variants isolated from patients who had no response to existing antiviral regimens after having received a variety of antiviral agents. Structural analyses revealed that the close contact of UIC-94017 with the main chains of the protease active-site amino acids (Asp-29 and Asp-30) is important for its potency and wide spectrum of activity against multi-PI-resistant HIV-1 variants. Considering the favorable pharmacokinetics of UIC-94017 when administered with ritonavir, the present data warrant that UIC-94017 be further developed as a potential therapeutic agent for the treatment of primary and multi-PI-resistant HIV-1 infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据